|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Here are two generic-drug companies that should hold up well, regardless of the current uncertainty.
Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for this week.
Adrian Adams, CEO of Auxilium, discusses the company's breakthrough with Xiaflex, as well as recent news surrounding its drug Testim.
Contributor Ken Shreve takes a look at the economic data and earnings reports slated for the coming week.
A play on Columbia Labs has the potential to be heads you win big, tails you lose bigger.
Smart acquisitions are yet another tailwind for this market that just won't quit.
Several factors got me thinking about health care today, and this company in particular.
Have the many stocks across a broad range of sectors been testing support or eroding its underpinnings?
Potential leaders are out there, but volume levels are less than desirable.